Published in Blood on January 11, 2008
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 2.09
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol (2008) 1.44
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy (2012) 1.27
Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens (2011) 1.18
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 1.15
Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy (2011) 1.11
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica (2012) 1.05
Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med (2009) 1.02
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One (2013) 1.02
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother (2015) 1.01
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res (2013) 1.00
Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) (2014) 0.94
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol (2015) 0.94
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol (2012) 0.93
Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica (2012) 0.92
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res (2010) 0.90
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med (2015) 0.89
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol (2015) 0.88
Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One (2013) 0.86
The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J (2015) 0.86
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. Oncoimmunology (2015) 0.84
A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs (2014) 0.84
Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy. J Transl Med (2009) 0.83
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell. Oncotarget (2014) 0.81
NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2. J Transl Med (2013) 0.80
Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm (2014) 0.80
Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother (2015) 0.79
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget (2016) 0.79
Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk. Oncoimmunology (2012) 0.77
"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy. Biomed Res Int (2015) 0.77
Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol (2016) 0.76
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation. Front Immunol (2017) 0.76
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells. Oncotarget (2016) 0.75
Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. Breast Cancer Res Treat (2016) 0.75
Manufacturing Natural Killer Cells as Medicinal Products. Front Immunol (2016) 0.75
Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients. Front Immunol (2017) 0.75
Natural Killer Cells: Angels and Devils for Immunotherapy. Int J Mol Sci (2017) 0.75
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood (2005) 3.99
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood (2010) 3.58
Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood (2009) 3.46
Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med (2005) 3.41
Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev (2006) 3.30
Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science (2004) 3.08
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med (2010) 2.89
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood (2009) 2.88
Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res (2003) 2.44
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood (2010) 2.33
Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood (2007) 2.32
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 2.04
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
Memory CD8+ T cells provide an early source of IFN-gamma. J Immunol (2003) 1.93
KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood (2009) 1.92
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy (2010) 1.85
CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med (2004) 1.80
Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet (2008) 1.76
Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol (2002) 1.66
Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood (2009) 1.62
Approach to the treatment of multiple myeloma: a clash of philosophies. Blood (2011) 1.57
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol (2011) 1.53
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52
Organ-specific features of natural killer cells. Nat Rev Immunol (2011) 1.48
Determination of structural principles underlying three different modes of lymphocytic choriomeningitis virus escape from CTL recognition. J Immunol (2004) 1.46
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood (2006) 1.45
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Pillars article: Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989. 340: 443-448. J Immunol (2007) 1.40
Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. Leuk Lymphoma (2009) 1.40
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 1.38
NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol (2004) 1.30
CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol (2010) 1.30
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood (2013) 1.26
Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica (2010) 1.26
Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol (2009) 1.24
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17
Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol (2008) 1.17
Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol (2005) 1.17
Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood (2009) 1.16
Functional analysis of human NK cells by flow cytometry. Methods Mol Biol (2010) 1.16
Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood (2011) 1.15
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy (2009) 1.14
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood (2010) 1.14
Natural killer and dendritic cell contact in lesional atopic dermatitis skin--Malassezia-influenced cell interaction. J Invest Dermatol (2002) 1.12
The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family. J Biol Chem (2003) 1.11
Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc Natl Acad Sci U S A (2004) 1.11
Natural killer cells in human autoimmunity. Curr Opin Immunol (2009) 1.11
NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J Immunol (2004) 1.11
KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol (2005) 1.10
Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol (2005) 1.10
Longitudinal analysis of the human T cell response during acute hantavirus infection. J Virol (2011) 1.09
Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood (2008) 1.08
Application of nine-color flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets. J Immunol Methods (2007) 1.07
2B4/CD48-mediated regulation of lymphocyte activation and function. J Immunol (2005) 1.07
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist (2011) 1.06
NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol (2011) 1.05
Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation (2004) 1.05
CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells. Blood (2012) 1.04
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol (2006) 1.03
Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood (2005) 1.02
Transmission of Toxoplasma gondii from infected dendritic cells to natural killer cells. Infect Immun (2009) 1.01
Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer (2010) 1.01
Triticum durum metallothionein. Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling. J Biol Chem (2005) 1.01
Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol (2003) 1.00
Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol (2005) 0.99
Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells. J Virol (2004) 0.99
Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol (2006) 0.98
Invasion and persistence of the neuroadapted influenza virus A/WSN/33 in the mouse olfactory system. Viral Immunol (2003) 0.98
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther (2012) 0.98
Spotlight on IL-22-producing NK cell receptor-expressing mucosal lymphocytes. Nat Immunol (2009) 0.98
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood (2013) 0.98
Lentiviral-mediated HoxB4 expression in human embryonic stem cells initiates early hematopoiesis in a dose-dependent manner but does not promote myeloid differentiation. Stem Cells (2008) 0.97
Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol (2005) 0.97
Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J Immunol (2008) 0.96
Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood (2011) 0.95
Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation. Eur J Immunol (2014) 0.95
Characterization of natural killer cell phenotype and function during recurrent human HSV-2 infection. PLoS One (2011) 0.94
Processing and degradation of exogenous prion protein by CD11c(+) myeloid dendritic cells in vitro. J Virol (2002) 0.94